Global Health Limited Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch
Global Health Limited, known for its Medanta brand, is navigating a significant expansion phase as it balances rapid bed capacity growth with the operational integration of new facilities like Noida. Investors will be focused on the margin trajectory as the company scales its footprint and the impact of rising employee costs on overall profitability.
| Results date | May 14, 2026 |
|---|---|
| Quarter | Q4 FY 2025-2026 |
| Previous quarter revenue | Rs 1,121 Crores |
| Previous quarter PAT | Rs 95 Crores |
| Previous quarter EBITDA margin | 21.8% |
| Net debt (latest quarter) | Rs 600 Crores |
| Market cap | Rs 32,251.51 Cr |
| CMP | Rs 1199.6 |
Global Health Limited Q4 Results Date and Time
The company has scheduled its board meeting for May 14, 2026, to consider the audited financial results for the quarter and year ended March 31, 2026.
What to expect from Global Health Limited's Q4 FY26 results
In its most recently reported quarter, Global Health Limited posted revenue of Rs 1,121 Crores, PAT of Rs 95 Crores, and an EBITDA margin of 21.8%. The company is currently managing a significant expansion pipeline, having increased its total bed count to 3,579 as of December 31, 2025, which contributed to a 59% occupancy rate for the quarter.
Management has guided for 5%-7% annual ARPOB growth over the next 2-3 years, while maintaining a focus on integrating new facilities like the 328-bed Noida hospital. The upcoming call will likely address the impact of a 36.3% YoY increase in employee benefits expense and the progress of new projects including the 400-bed Varanasi hospital and the Rs 322 Crore medical college.
Key Things To Watch
Performance vs Guidance Tracking
- ARPOB Growth — 5%-7% annually — Q3 FY26 achieved 9.9% YoY
- Noida Ramp-up — Losses near peak in Q3 — update on trajectory toward breakeven
- Occupancy Rates — 59% in Q3 FY26 — watch for stabilization post-expansion
- Developing Hospital Margins — 31.7% in Q3 FY26 — trend monitoring
Strategic Expansion Updates
- Noida facility — Full 550-bed capacity build-out timeline
- South Delhi & Pitampura — Commissioning timeline updates
- Indore Cancer Care acquisition — Integration progress ahead of September 30, 2026 long-stop date
Financial Performance Indicators
- EBITDA margin — Watch for Noida facility improvement from the 21.8% consolidated level
- Capital allocation — FY27 capex guidance below Rs 500 crores — confirm spending priorities
- International patient revenue — Sustainability of the 30% YoY growth seen in Q3
Risks and headwinds to monitor
- Labour cost inflation — Employee benefits expense increased 36.3% YoY
- Talent retention — Update on senior doctor attrition and recruitment pipeline
- CGHS rate revision — Any updates on financial impact assessment
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
When will Global Health Limited announce Q4 FY 2025-2026 results?
Global Health Limited is scheduled to announce its results on May 14, 2026.
What was Global Health Limited's revenue in its previous quarter?
The company reported consolidated revenue of Rs 1,121 Crores for the quarter ended December 31, 2025.
What is Global Health Limited's net debt position?
As of December 2025, the company reported a net cash position of approximately Rs 600 Crores, with total cash over Rs 1,200 Crores and loans of about Rs 600 Crores.
When does the company expect the Noida facility to break even?
Management has declined to provide specific projections for the Noida facility's breakeven timeline. They have indicated that losses were near their peak during the third quarter of FY26.
What is the company's outlook for ARPOB growth?
Management has guided for 5%-7% annual ARPOB growth over the next 2-3 years. They noted that this growth is dependent on length of stay and case mix.